Colitis Due to Campylobacter jejuni/coli: Ceftriaxone is Not Effective
- *Corresponding Author:
- Stephane Emonet
Service of Infectious Diseases, Department of Medical Specialties
Geneva University Hospitals, Gabrielle-Perret-Gentil 4
CH-1211 Geneva 14, Switzerland
Tel: +41022 3727323
E-mail: [email protected]
Received Date: May 08, 2017; Accepted Date: May 17, 2017; Published Date: May 20, 2017
Citation: Emonet S, Redzepi B, Riat A, Cherkaoui A, Lipsky BA, et al. (2017) Colitis Due to Campylobacter jejuni/coli: Ceftriaxone is Not Effective. J Gerontol Geriatr Res 6:426. doi: 10.4172/2167-7182.1000426
Copyright: © 2017 Emonet S, et al. This is an open-access article distributed under the terms of the creative commons attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: Ceftriaxone is often prescribed empirically for patients hospitalized with abdominal pain and fever. If stools culture from such a patient yields Campylobacter jejuni or Campylobacter coli (C. jejuni/coli), clinicians ask about its susceptibility to ceftriaxone, to which it is not routinely tested. We report a case of colitis that raised this question. As we couldn’t find the answer in the published literature, we investigated the sensitivity of strains of C. jejuni/coli to ceftriaxone in our hospital.
Methods: We conducted a retrospective study of all strains of C. jejuni and C. coli isolated from specimens of infected patients seen in our tertiary care university-affiliated hospital in Switzerland between March 2009 and December 2010. Campylobacter strains were identified to the species level with matrix-assisted laser desorption ionization - time of flight (MALDI-TOF) mass spectrometry and antimicrobial susceptibilities were determined by Etest.
Results: Among 108ËÃ¯Â¿Â½C. jejuni and 14ËÃ¯Â¿Â½C. coli isolates, only 1.6% were fully susceptible to ceftriaxone. Overall, 95.9% of our strains were susceptible to erythromycin but 52.5% of C. jejuni/coli were resistant to ciprofloxacin.
Conclusion: Our results suggest that ceftriaxone should be considered ineffective for the treatment of Campylobacter jejuni/coli infections, the major cause of gastro-enteritis in Europe. In the light of increasing resistance to fluoroquinolones, cases of severe Campylobacter colitis or bacteraemia may require a short course of macrolides.